Eagle Capital Management 13F: Cuts Humana (HUM) Stake by $114M

Eagle Capital Management has trimmed its holdings in Humana Inc. (NYSE: HUM). The firm reduced its position by 287,324 shares, bringing its total stake to 2,967,074 shares. This reduction, as reported in its latest 13F filing, represents an 8.8% decrease in its holdings, now valued at approximately $1.1 billion.

What Changed in Eagle Capital Management's Humana Position

Eagle Capital Management cut its Humana stake by 287,324 shares, reducing its holdings to 2,967,074 shares. This marks an 8.8% decrease from its previous count of 3,254,398 shares, reflecting a strategic adjustment in its portfolio.

Other Institutional Activity in Humana

Other institutional investors have also made moves in Humana. Dodge & Cox increased its holdings by 90,238 shares, ending with 11,380,673 shares worth about $1.97 billion. BlackRock, Inc. reduced its position by 433,742 shares, now holding 10,199,055 shares valued at $1.77 billion. Vanguard Capital Management LLC added 7,838,762 shares, bringing its total to that same amount, valued at approximately $1.36 billion. Pzena Investment Management LLC significantly increased its stake by 1,398,774 shares, now holding 5,470,982 shares worth about $948.6 million.

Humana Inc. Stock Down 7.1%

Shares of Humana Inc. (NYSE: HUM) traded near $371.39 recently. The company has a market capitalization of $45.5 billion, with a forward P/E ratio of 24.1 and a beta of 0.771. Over the past 52 weeks, the stock has ranged from $163.11 to $379.49. Its 50-day moving average stands at $263.46, while the 200-day moving average is $247.22.

Recent Earnings

Humana reported revenue of $137.2 billion, experiencing a revenue growth of 23.5%. The company's EPS is $9.36, with a net margin of 0.824% and a return on equity of 6.28%. Humana is expected to announce its next earnings on July 29, 2026.

Dividend

Humana offers a dividend rate of $3.54 per share, yielding 0.96%. The dividend payout ratio is 37.78%, indicating a balanced approach to rewarding shareholders while retaining capital for growth.

Insider Buying and Selling at Humana Inc.

Several insiders have been active at Humana recently. President and CEO James Rechtin purchased 35,633 shares on May 1, 2026. Other significant purchases include Sanjay Shetty, President of CenterWell, who bought 9,945 shares, and Japan Mehta, CIO, who acquired 9,448 shares, all on the same date. Chief Financial Officer Celeste Mellet sold 15,387 shares, also on May 1, 2026.

Analysts Set New Price Targets

Analyst firms have recently maintained their ratings on Humana. On June 11, 2026, Evercore ISI Group maintained a "hold" rating with a $370 price target. Mizuho maintained a "buy" rating on June 8, 2026, with a target of $390. Meanwhile, Morgan Stanley kept a "sell" rating with a $249 target on June 4, 2026. The consensus recommendation is a "hold," with a mean target price of $301.63 based on 24 analyst opinions.

About Humana Inc.

Humana Inc., headquartered in Louisville, Kentucky, is a leading provider of medical and specialty insurance products in the United States. The company operates through its Insurance and CenterWell segments, offering a range of services including Medicare Advantage, prescription drug plans, and primary care centers. Led by CEO James A. Rechtin, Humana employs approximately 67,060 people.

Bottom Line

Eagle Capital Management's recent reduction in Humana shares reflects a strategic shift in its investment approach. Investors closely watch such filings for insights into institutional sentiment. It's important to remember that 13F filings are backward-looking and may not represent current positions.